Mikael Dolsten
CIK 1437590 · President R&D · last filed 2026-06-02
Mikael Dolsten is a President R&D who has filed 116 SEC Form 4 insider transactions across 6 companies since 2008. The most recent filing shows the insider sold $216.7K of A on Jun 2, 2026. Across all open-market trades the lifetime net is −$31.7M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $9.2M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$9.21M
6
116
-$31.70M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| A | Director | 5,548 | $129.84 | $720.4K | -$606.2K | 8 | 2026-06-02 |
| Apellis Pharmaceuticals, Inc. (APLS) Delisted | Director | 0 | $41.03 | $0 | $0 | 2 | 2026-05-14 |
| RCKTW | Director | 44,220 | $0.01 | $429 | $0 | 3 | 2025-07-18 |
| PFE | President R&D | 323,710 | $26.21 | $8.48M | -$31.09M | 93 | 2024-09-16 |
| KPTI | Director | — | $9.50 | — | $0 | 8 | 2021-05-21 |
| WYETH (WYEp) Delisted | Sr. VP & Pres., Wyeth Research | — | — | — | $0 | 1 | 2008-06-18 |
Recent Filings
116 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-02 | A | Sell (S) | −1,600 | -$216.7K | EDGAR |
| 2026-05-14 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Mixed | −28,624 | $0 | EDGAR |
| 2026-03-23 | A | Grant (A) | +2,158 | $241.2K | EDGAR |
| 2026-03-03 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Grant (A) | +14,312 | $0 | EDGAR |
| 2025-12-03 | A | Sell (S) | −2,600 | -$389.5K | EDGAR |
| 2025-07-18 | RCKTW | Grant (A) | +30,000 | $0 | EDGAR |
| 2025-04-24 | RCKTW | Other (J) | +14,220 | $0 | EDGAR |
| 2025-03-18 | A | Grant (A) | +1,819 | $220.4K | EDGAR |
| 2024-09-16 | PFE | Mixed | — | $0 | EDGAR |
| 2024-09-11 | RCKTW | Grant (A) | — | $0 | EDGAR |